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ABSTRACT 
Acinetobacter baumannii is a serious nosocomial pathogen with a high propensity to 
cause outbreaks. Whilst outbreaks of A. baumannii have been reported in many 
regions worldwide, few data are available from East Africa. In this study, 25 A. 
baumannii isolates derived from a single institution located in Nairobi, Kenya, 
between September 2010 and September 2011 were examined. Antimicrobial 
susceptibility testing was performed by the disk diffusion method and the relatedness 
among the isolates was examined by pulsed-field gel electrophoresis, repetitive 
sequence-based PCR (rep-PCR) and multilocus sequence typing. The examined 
isolates clustered into three distinct groups. The most prevalent sequence type (ST) 
was ST110 (17 isolates), followed by ST92 (5 isolates) and ST109 (3 isolates). All 
isolates exhibited resistance to cefepime, ceftazidime, ticarcillin/clavulanic acid, 
cefotaxime/clavulanic acid, piperacillin/tazobactam, cefoxitin, ciprofloxacin, 
gentamicin, nitrofurantoin, fosfomycin trometamol, trimethoprim/sulfamethoxazole, 
amikacin, meropenem and imipenem, with the exception of four isolates. Two 
isolates belonging to ST92 and two isolates belonging to ST109 were susceptible to 
amikacin; one of these amikacin-susceptible ST109 isolates was also susceptible to 
meropenem and imipenem. All isolates were positive for OXA 51-like and all 
carbapenem-resistant isolates were OXA-23 positive. 
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1. Introduction 
Acinetobacter baumannii is a Gram-negative coccobacillus that has emerged as a 
serious healthcare-associated pathogen in recent years. Acinetobacter baumannii 
infection may result in pneumonia, bloodstream infection, urinary tract infection, 
meningitis and wound infection as well as other manifestations of infection [1]. 
 
Acinetobacter baumannii has a high propensity to cause nosocomial outbreaks, 
possibly due to its persistence in the hospital environment and its remarkable ability 
to acquire drug resistance. Several studies indicate significantly increased resistance 
rates in epidemic A. baumannii strains compared with sporadic strains [1]. 
 
To distinguish outbreak strains from epidemiologically unrelated A. baumannii 
strains, typing methods such as pulsed-field gel electrophoresis (PFGE), repetitive 
sequence-based PCR (rep-PCR) and multilocus sequence typing (MLST) are 
employed [1]. PFGE and rep-PCR have been demonstrated to be more 
discriminatory than MLST, which is routinely used to put epidemiological information 
in a global context [2]. 
 
Whilst outbreaks of A. baumannii have been reported in many regions worldwide, 
including Europe, North America, Latin America, Australia, Asia, the Middle East and 
South Africa [1], few data are available for East African A. baumannii isolates. In the 
current study, antibiotic susceptibility testing, MLST, rep-PCR and PFGE were 
performed for 25 A. baumannii strains isolated at Aga Khan University Hospital, 
Nairobi (AKUH, N), Kenya. 
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2. Materials and methods 
2.1. Collection and identification of Acinetobacter baumannii isolates 
The 25 non-repetitive A. baumannii isolates investigated in this study were cultivated 
at the Division of Microbiology of AKUH, N from the following specimen types: 9 A. 
baumannii isolates were derived from tracheal aspirates, 5 isolates were from pus 
swabs, 3 were from nasal swabs, 2 isolates each were from sputum, cerebrospinal 
fluid (CSF) and urine, and 1 isolate each was derived from blood and unspecified 
tissue. The two CSF isolates and the tissue sample isolate were considered clinically 
significant and the patients were specifically treated with colistin. Both CSF samples 
came from patients with ventricular shunts. All isolates were collected from 
September 2010 to September 2011. Although a previous outbreak of multiresistant 
Acinetobacter in the intensive care unit (ICU) [3] had been stopped with highly 
stringent infection control measures, multidrug-resistant Acinetobacter continued to 
be isolated from patients admitted to the hospital. Fourteen of the patients had a 
history of prior admission to the hospital, whilst eight had a history of admission to 
various other hospitals in Nairobi. Thirteen of the patients were in the ICU at the time 
of specimen collection. However, their hospital stay was at different time periods. 
 
Identification of the isolates as A. baumannii was reconfirmed by 16S rDNA 
sequencing in addition to PCR detection of the blaOXA-51-like oxacillinase [4,5]. 
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2.2. Antimicrobial susceptibility testing 
Antimicrobial susceptibility of the clinical isolates was determined by the disk 
diffusion method on Mueller–Hinton agar (Oxoid Ltd., Basingstoke, UK) according to 
Clinical and Laboratory Standard Institute (CLSI) recommendations [6]. Antibiotic 
disks were supplied by Becton, Dickinson & Co. (Franklin Lakes, NJ) and the 
following antibiotics were tested: amikacin; cefepime; meropenem; imipenem; 
ceftazidime; ticarcillin/clavulanic acid; cefotaxime/clavulanic acid; 
piperacillin/tazobactam; cefoxitin; ciprofloxacin; gentamicin; nitrofurantoin; 
fosfomycin trometamol; and trimethoprim/sulfamethoxazole. 
 
2.3. Bacterial genotyping 
Genomic DNA was extracted using an UltraClean® Microbial DNA Isolation Kit (MO 
BIO Laboratories, Carlsbad, CA) as recommended by the manufacturer and was 
used for MLST and rep-PCR analysis. MLST was performed as previously described 
[7], making use of the A. baumannii MLST website (http://pubmlst.org/abaumannii/) 
developed by Keith Jolley and located at the University of Oxford (Oxford, UK). rep-
PCR and PFGE typing were used for the increased resolution required for 
investigation of clonality in outbreak analysis. 
 
rep-PCR typing was performed using a DiversiLab Acinetobacter Kit (bioMérieux, 
Marcy l’Étoile, France). DiversiLab fingerprints were analysed with DiversiLab 
software using the Pearson correlation statistical method to determine clonal 
relationships. Isolates were considered as clonal when the rep-PCR patterns showed 
≥95% similarity. 
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PFGE was conducted with the restriction enzyme ApaI using a CHEF-DR® III system 
(Bio-Rad, Hercules, CA) as previously described [8]. 
 
2.4. Resistance gene analysis 
Presence of the metallo-β-lactamase gene blaIMP as well as the extended-spectrum 
β-lactamase (ESBL) gene blaPER-1 and the AmpC β-lactamase gene blaCMY-2 was 
determined by PCR [9–11]. The occurrence of carbapenem-hydrolysing class D β-
lactamase (oxacillinase) (CHDL) genes, namely blaOXA-51-like, blaOXA-23-like and blaOXA-
58-like, was determined by PCR [12]. Detection of insertion sequence ISAba1 
upstream of blaOXA-51-like was performed using PCR [13]. 
 
3. Results and discussion 
All isolates were resistant to cefepime, ceftazidime, ticarcillin/clavulanic acid, 
cefotaxime/clavulanic acid, piperacillin/tazobactam, cefoxitin, ciprofloxacin, 
gentamicin, nitrofurantoin, fosfomycin trometamol and 
trimethoprim/sulfamethoxazole. In addition, all isolates except one (AKUH AB008) 
showed resistance to meropenem and imipenem. In addition to being susceptible to 
meropenem and imipenem, isolate AKUH AB008 was also susceptible to amikacin, 
as were three other isolates. Resistance profiles of meropenem, imipenem and 
amikacin are illustrated in Fig. 1. 
 
These investigations showed that three clones of A. baumannii were found within 
this Kenyan institution. The 25 isolates investigated in this study grouped into three 
different sequence types (STs) belonging to three different clonal complexes (CCs). 
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The most prevalent sequence type was ST110 (17 isolates), followed by ST92 (5 
isolates) and ST109 (3 isolates). Worldwide, ST92 and the associated CC92, also 
known as European clone 2 or worldwide clonal lineage 2, represent the most 
widespread sequence type(s). ST109 is part of clonal cluster CC1, which is also 
found worldwide (http://pubmlst.org/abaumannii/). 
 
In this study, the strains of each sequence type shared similar PFGE and rep-PCR 
profiles. It is worth noting that all of the ST110 isolates were resistant to all of the 
antibiotics investigated, whilst two isolates of ST92 and two isolates of ST109 were 
susceptible to amikacin; one of the amikacin-susceptible ST109 isolates was also 
susceptible to meropenem and imipenem. Isolates of the same sequence type 
clustered together when analysed by the DiversiLab rep-PCR typing method and 
PFGE (Fig. 1). 
 
The naturally occurring blaOXA-51-like gene was detected in all 25 A. baumannii isolates 
and the acquired CHDL blaOXA-23 gene was present in all meropenem-resistant 
isolates, whilst the meropenem-susceptible isolate was negative for the blaOXA-23-like 
gene. The blaOXA-58-like gene was not detected, and all isolates tested negative for 
blaPER-1 and blaCMY-2. Two isolates (AKUH 012 and 015), both ST109, were positive 
for the element ISAba1–blaOXA-51-like, whilst the remaining 23 isolates were negative 
for the presence of this element. 
 
ST110 A. baumannii have been previously found in India [14], South Korea [15] and 
Australia [16]; however, in these settings ST110 did not account for the majority of 
strains. Although in the current study ST110 isolates were resistant to all of the 
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antibiotics investigated, invariably producing OXA-23, antibiotic susceptibility and 
resistance mechanisms of ST110 were less uniform in other settings [14,15]. 
 
Whilst in the current study blaOXA-23 was the major carbapenem resistance 
mechanism detected, a previous report from AKUH, N has shown the antibiotic 
resistance gene structure ISAba1–blaOXA-23 to be the main mechanism of 
carbapenemase resistance among 10 Kenyan A. baumannii isolates [3]. In the 
current study, two strains of ST109 A. baumannii harboured the ISAba1–blaOXA-51-like 
element. However, the carbapenemase-producing genes blaIMP and blaOXA-58 as well 
as the ESBL blaPER-1 and AmpC-producing gene blaCMY-2 were not detected. 
 
Thus, the molecular epidemiology of carbapenem-resistant A. baumannii isolates 
from a single hospital in Kenya reveals the presence of organisms associated with 
infection elsewhere in the world. The time course of the outbreaks is illustrated in 
Fig. 2. It is noteworthy that the first isolate of each sequence type was in a patient 
transferred from another hospital. Unfortunately, as has occurred elsewhere in the 
world, introduction of strains from other hospitals and person-to-person spread of 
hospital-adapted strains of A. baumannii appears to be occurring in Kenyan 
healthcare facilities. 
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Fig. 1. Molecular typing, antimicrobial resistance profile and source of isolation of 25 
Acinetobacter baumannii clinical isolates. Of note, all isolates were resistant to all 
antibiotics tested, including meropenem (MEM), imipenem (IMP) and amikacin (AN), 
with the exception of four isolates; isolates 19, 21 and 23 were susceptible to AN and 
isolate 24 was susceptible to MEM, IMP and AN. R, resistant; S, susceptible. ICU, 
intensive care unit; HDU, haemodialysis unit. 
 
Fig. 2. Time course of Acinetobacter baumannii outbreaks according to sequence 
type (ST). Isolates are depicted with diamonds; isolates within circles were derived 
from patients staying in the intensive care unit or haemodialysis unit, and isolates 
outside circles were derived from patients hospitalised in other wards. 
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